These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 23786960)
1. Maintenance therapy in advanced non-small cell lung cancer: a prime-time for change? Chan OS; Yeung RM; Lee AW Chin Med J (Engl); 2013 Jun; 126(12):2390-8. PubMed ID: 23786960 [No Abstract] [Full Text] [Related]
2. Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer. Fidias P; Novello S J Clin Oncol; 2010 Dec; 28(34):5116-23. PubMed ID: 21041704 [TBL] [Abstract][Full Text] [Related]
3. Vinorelbine for treatment of advanced non-small-cell lung cancer. Med Lett Drugs Ther; 1995 Aug; 37(955):72-3. PubMed ID: 7630328 [No Abstract] [Full Text] [Related]
4. Meta-analysis of single agents in the chemotherapy of NSCLC: what do we want to know? Bahl A; Falk S Br J Cancer; 2001 May; 84(9):1143-5. PubMed ID: 11336462 [No Abstract] [Full Text] [Related]
5. Oral second-line chemotherapy for advanced non-small-cell lung cancer: the bottom line. Gandara DR; Davies AM J Clin Oncol; 2006 Jun; 24(18):2700-1. PubMed ID: 16682720 [No Abstract] [Full Text] [Related]
7. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system. Zeng X; Peng L; Li J; Chen G; Tan C; Wang S; Wan X; Ouyang L; Zhao Z Clin Ther; 2013 Jan; 35(1):54-65. PubMed ID: 23328269 [TBL] [Abstract][Full Text] [Related]
8. Platinums in lung cancer: sufficient or necessary? Bunn PA J Clin Oncol; 2005 May; 23(13):2882-3. PubMed ID: 15728220 [No Abstract] [Full Text] [Related]
9. [Effects, possibilities and limits. Cytostatic therapy of small cell and non-small cell lung cancer]. Bergman B Lakartidningen; 1997 Apr; 94(18):1702, 1707-10. PubMed ID: 9182178 [No Abstract] [Full Text] [Related]
10. Maintenance therapy: a new treatment paradigm in advanced nonsmall-cell lung cancer. Gridelli C Curr Opin Oncol; 2013 Mar; 25(2):105-6. PubMed ID: 23385858 [No Abstract] [Full Text] [Related]
11. Targeted therapy for non-small cell lung cancer. Jett JR; Carr LL Am J Respir Crit Care Med; 2013 Oct; 188(8):907-12. PubMed ID: 23721055 [TBL] [Abstract][Full Text] [Related]
14. Potential evaluation of the incremental cost-effectiveness of paclitaxel in advanced non-small-cell lung cancer (Eastern Cooperative Oncology Group 5592). Hillner BE J Natl Cancer Inst Monogr; 1995; (19):65-7. PubMed ID: 7577209 [No Abstract] [Full Text] [Related]
15. Silk purse in Atlanta: a commentary on SWOG 9509, an advanced non-small cell lung cancer trial. Gralla RJ Oncologist; 1999; 4(3):188-90. PubMed ID: 10394586 [No Abstract] [Full Text] [Related]
16. [Therapy for non-small-cell lung carcinoma (NSCLC) in stage IV]. Deppermann KM; Huber RM; Laack E; Reck M; Serke M; von Pawel J Onkologie; 2006 Sep; 29 Suppl 2():15-9. PubMed ID: 16974123 [No Abstract] [Full Text] [Related]
17. [Local and systemic therapy of non-small cell lung carcinoma (NSCLC)]. Gatzemeier U; Griesinger F; Huber RM; Thomas M Onkologie; 2010; 33 Suppl 5():1. PubMed ID: 20523100 [No Abstract] [Full Text] [Related]
18. Re-evaluating duration of therapy in advanced non-small-cell lung cancer: is it really duration or is it more about timing and exposure? Socinski MA J Clin Oncol; 2009 Jul; 27(20):3268-70. PubMed ID: 19470913 [No Abstract] [Full Text] [Related]
19. [Therapeutic management of non-small-cell lung carcinoma (NSCLC) of stage III A]. Mornex F Rev Pneumol Clin; 2001 Nov; 57(5 Pt 2):S29-32. PubMed ID: 11924239 [No Abstract] [Full Text] [Related]